DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Sheraton Philadelphia Downtown Hotel

2024 年 10 月 24 日 7:00 上午 - 2024 年 10 月 25 日 7:00 下午

201 North 17th Street, Philadelphia, PA 19103

Real-World Evidence Conference

Translating Insights into Real-World Value

Call for Abstracts Closes in

DAYS

HOURS

MINUTES

SECONDS

概览

Conference: October 24-25, 2024


In a market that is constantly adapting and adjusting to the needs of the healthcare field, real-world evidence (RWE) is becoming increasingly important for regulatory and reimbursement decision-making. Historically used for post-market safety monitoring, RWE is now integrated throughout the product development lifecycle, and has led to the real-time analysis of data to better understand and gain insights on disease, approaches to treatment, and how to substantiate coverage decisions.

DIA’s Real-World Evidence Conference will explore new, innovative applications of RWE, and deliver cutting-edge insights to leverage this knowledge to advance healthcare decision-making.

While we develop our 2024 agenda, please take a moment to review the last year final agenda


Participant Testimonials

DIA RWE is the best RWE-related event I've attended - it has compelling speakers, strong education opportunities, and a great collective of attendees. – Nicholaas Honig, JD, Senior Regulatory Counsel, Aetion

Great meeting. Very strong content. Was a really efficient way for me to catch up on RWD/E happenings over the past year! – Meredith Zozus, PhD, Professor; Division Chief and Director, Clinical Research Informatics, University of Texas Health Science Center

Featured

Want to learn more about Real-World Evidence Conference? You've come to the right site!

Highlights & Features

谁应该参加?

  • Conference Designed For:

    • Academia
    • Clinical Research
    • Data analytics
    • Epidemiology
    • Health Economics and Outcomes Research
    • Pharmacovigilance
    • Policy
    • Real-World Evidence
    • Real-World Data
    • Regulatory Science
    • Technology development

项目委员会

  • David  Martin, MD, MPH
    David Martin, MD, MPH Vice President, Global Head RWE
    Moderna, United States
  • Jaclyn  Bosco, PhD, MPH, FISPE
    Jaclyn Bosco, PhD, MPH, FISPE Vice President and Global Head of Epidemiology
    IQVIA, United States
  • John  Concato, MD, MPH, MS
    John Concato, MD, MPH, MS Associate Director for Real-World Evidence Analytics, OMP, CDER
    FDA, United States
  • Diane  Gubernot, DrPH, MPH
    Diane Gubernot, DrPH, MPH Epidemiologist
    US FDA, United States
  • Rachele  Hendricks-Sturrup, DrSc, MA, MSc
    Rachele Hendricks-Sturrup, DrSc, MA, MSc Research Director, Real-World Evidence
    Duke-Robert J. Margolis, MD, Center for Health Policy, United States
  • Camille  Jackson
    Camille Jackson Director, Regulatory Policy; Legal and Regulatory
    Flatiron Health , United States
  • Charles  Lee, MBA, MS
    Charles Lee, MBA, MS Executive Regulatory Science Director
    AstraZeneca, United States
  • Alexander  Liede, PhD, MSc
    Alexander Liede, PhD, MSc Senior Director, Global Epidemiology
    Abbvie, Ireland
  • Sarah  Martin, PhD, MS
    Sarah Martin, PhD, MS Senior Director - Global Regulatory Policy (Oncology)
    Eli Lilly & Co., United States
  • Brittany  McKelvey, PhD
    Brittany McKelvey, PhD Director, Regualtory Affairs
    Friends of Cancer Research, United States
  • Keri  Monda, PhD, MS
    Keri Monda, PhD, MS Executive Director, Center for Observational Research
    Amgen, United States

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。